Literature DB >> 8659541

Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening.

M Telatar1, Z Wang, N Udar, T Liang, E Bernatowska-Matuszkiewicz, M Lavin, Y Shiloh, P Concannon, R A Good, R A Gatti.   

Abstract

We have examined the distal half of the ataxia-telangiectasia (A-T) gene transcript for truncation mutations in 48 A-T affecteds. We found 21 mutations; 4 of the mutations were seen in more than one individual. Genotyping of the individuals sharing mutations, by using nearby microsatellite markers, established that three of the four groups shared common haplotypes, indicating that these were probably founder effects, not public mutations. The one public mutation was found in two American families, one of Ashkenazi Jewish background and the other not. Most truncations deleted the PI3-kinase domain, although some exceptions to this were found in patients with typical A-T phenotypes. All patients not previously known to be consanguineous were found to be compound heterozygotes when mutations could be identified--that is, normal and abnormal protein segments were seen on SDS-PAGE gels. All 48 patients gave RT-PCR products, indicating the presence of relatively stable mRNAs despite their mutations. These results suggest that few public mutations or hot spots can be expected in the A-T gene and that epidemiological studies of A-T carrier status and associated health risks will have to be designed around populations with frequent founder-effect mutations, despite the obvious limitations of this approach.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659541      PMCID: PMC1915099     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  20 in total

1.  Possible use of established cell lines for MLR locus typing.

Authors:  E A Svedmyr; W Leibold; R A Gatti
Journal:  Tissue Antigens       Date:  1975-04

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes.

Authors:  A Ganguly; M J Rock; D J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

Review 4.  Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis.

Authors:  R A Gatti; E Boder; H V Vinters; R S Sparkes; A Norman; K Lange
Journal:  Medicine (Baltimore)       Date:  1991-03       Impact factor: 1.889

5.  Genetic haplotyping of ataxia-telangiectasia families localizes the major gene to an approximately 850 kb region on chromosome 11q23.1.

Authors:  R A Gatti; E Lange; G Rotman; X Chen; N Uhrhammer; T Liang; S Chiplunkar; L Yang; N Udar; S Dandekar; S Sheikhavandi; Z Wang; H M Yang; J Polikow; M Elashoff; M Teletar; O Sanal; L Chessa; C McConville; M Taylor; Y Shiloh; O Porras; A L Borresen; R D Wegner; C Curry; S Gerken; K Lange; P Concannon
Journal:  Int J Radiat Biol       Date:  1994-12       Impact factor: 2.694

6.  Protein truncation test (PTT) for rapid detection of translation-terminating mutations.

Authors:  P A Roest; R G Roberts; S Sugino; G J van Ommen; J T den Dunnen
Journal:  Hum Mol Genet       Date:  1993-10       Impact factor: 6.150

7.  Localization of an ataxia-telangiectasia gene to chromosome 11q22-23.

Authors:  R A Gatti; I Berkel; E Boder; G Braedt; P Charmley; P Concannon; F Ersoy; T Foroud; N G Jaspers; K Lange
Journal:  Nature       Date:  1988-12-08       Impact factor: 49.962

8.  Breast and other cancers in families with ataxia-telangiectasia.

Authors:  M Swift; P J Reitnauer; D Morrell; C L Chase
Journal:  N Engl J Med       Date:  1987-05-21       Impact factor: 91.245

9.  Incidence of cancer in 161 families affected by ataxia-telangiectasia.

Authors:  M Swift; D Morrell; R B Massey; C L Chase
Journal:  N Engl J Med       Date:  1991-12-26       Impact factor: 91.245

10.  Predominance of null mutations in ataxia-telangiectasia.

Authors:  S Gilad; R Khosravi; D Shkedy; T Uziel; Y Ziv; K Savitsky; G Rotman; S Smith; L Chessa; T J Jorgensen; R Harnik; M Frydman; O Sanal; S Portnoi; Z Goldwicz; N G Jaspers; R A Gatti; G Lenoir; M F Lavin; K Tatsumi; R D Wegner; Y Shiloh; A Bar-Shira
Journal:  Hum Mol Genet       Date:  1996-04       Impact factor: 6.150

View more
  23 in total

Review 1.  The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone.

Authors:  R A Gatti; S Becker-Catania; H H Chun; X Sun; M Mitui; C H Lai; N Khanlou; M Babaei; R Cheng; C Clark; Y Huo; N C Udar; R K Iyer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

2.  ATM protein synthesis patterns in sporadic breast cancer.

Authors:  R Kairouz; R A Clarke; P J Marr; D Watters; M F Lavin; J H Kearsley; C S Lee
Journal:  Mol Pathol       Date:  1999-10

3.  Global analysis of ATM polymorphism reveals significant functional constraint.

Authors:  Y R Thorstenson; P Shen; V G Tusher; T L Wayne; R W Davis; G Chu; P J Oefner
Journal:  Am J Hum Genet       Date:  2001-07-03       Impact factor: 11.025

4.  Isolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype.

Authors:  N Zhang; P Chen; K K Khanna; S Scott; M Gatei; S Kozlov; D Watters; K Spring; T Yen; M F Lavin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

5.  Characterisation of ATM mutations in Slavic Ataxia telangiectasia patients.

Authors:  Jana Soukupova; Petr Pohlreich; Eva Seemanova
Journal:  Neuromolecular Med       Date:  2011-08-11       Impact factor: 3.843

6.  Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer.

Authors:  Shaun P Scott; Regina Bendix; Philip Chen; Raymond Clark; Thilo Dork; Martin F Lavin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

7.  ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer.

Authors:  T Stankovic; A M Kidd; A Sutcliffe; G M McGuire; P Robinson; P Weber; T Bedenham; A R Bradwell; D F Easton; G G Lennox; N Haites; P J Byrd; A M Taylor
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

Review 8.  SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models.

Authors:  Richard A Gatti
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

9.  Gene expression phenotype in heterozygous carriers of ataxia telangiectasia.

Authors:  Jason A Watts; Michael Morley; Joshua T Burdick; Jennifer L Fiori; Warren J Ewens; Richard S Spielman; Vivian G Cheung
Journal:  Am J Hum Genet       Date:  2002-09-11       Impact factor: 11.025

10.  Nonaminoglycoside compounds induce readthrough of nonsense mutations.

Authors:  Liutao Du; Robert Damoiseaux; Shareef Nahas; Kun Gao; Hailiang Hu; Julianne M Pollard; Jimena Goldstine; Michael E Jung; Susanne M Henning; Carmen Bertoni; Richard A Gatti
Journal:  J Exp Med       Date:  2009-09-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.